A B S T R A C T Extracts of tumors from 32 patients with the ectopic ACTH syndrome were subjected to simultaneous bioassay and radioimmunoassays for ACTH. Radioimmunoassays were performed using three antisera, one of which reacts with the extreme N-terminal 1-13 amino acid sequence of ACTH, the second with the N-terminal 1-23 sequence of the ACTH molecule, and the third with the C-terminal 25-39 amino acid sequence of ACTH. There was, in general, good correlation between bioactivity and N-terminal ACTH immunoreactivity. However, there were large excesses of both extreme N-terminal and C-terminal immunoreactive materials in most tumor extracts, which were not found in extracts of three human pituitaries. Three tumor extracts were subjected to molecular sieve chromatography on Sephadex G-50 fine resin. The bioactive ACTH eluted in the same fractions as pituitary ACTH (mol wt 
INTRODUCTION
Partial characterization of the corticotropin extracted from tumors of patients with the ectopic adrenocorticotropic hormone (ACTH)1 syndrome (1, 2) has shown it to be very similar to pituitary corticotropin in a variety of biologic, physicochemical, and immunologic test systems (3, 4) . The precise structure of the tumor hormone has not been determined, however. In order to characterize tumor ACTH more fully, we have exploited a combination of ACTH bioassay, radioimmunoassays, immunologic neutralization, immunoadsorption, and gel filtration. Tumor extracts were subjected to bioassay and to radioimmunoassays utilizing ACTH antisera which react with three different portions of the ACTH molecule. The quantity of ACTH bioactivity was then correlated with the quantity of immunoreactive ACTH in each tumor extract. Finally, experiments were performed using gel filtration and immunologic neutralization and adsorption to determine if the major bioactive and immunoreactive components of a tumor extract were parts of the same molecule or were physically separable. 1Abbreviations used in this paper: ACTH, adrenocorticotropic hormone. MSH, melanocyte-stimulating hormone.
ACTH radioimmunoassays. Immunoreactive ACTH concentration was estimated by modifications of the method previously reported from this laboratory (13) . Highly purified human ACTH (Lerner-Upton-Lande preparation 8B) was used both for iodination and as reference standard.
ACTH was labeled with 'I or 'I by minor modifications of the method of Hunter and Greenwood (14) . Specific activities of 800-1,000 and 150-200 ,Ci/g were achieved, respectively. Each extract or plasma sample was assayed in duplicate at three or more dilutions. Extracts were diluted in acidified human albumin solution (15) ; plasma samples were diluted in 6,000 g ACTH-free plasma from dexamethasone-treated subjects. The mixtures were incubated in 10 X 75-mm polypropylene tubes (Falcon Plastics, Div. of B-D Laboratories, Inc., Los Angeles, Calif.) for 3-6 days at 40C. Separation of antibody-bound labeled ACTH from free labeled ACTH was achieved by the chromatoelectrophoretic system of Yalow and Berson (16) or, in more recent experiments, by the precipitation of antibody-bound ACTH with polyethylene glycol (7) . When antibody-bound ACTH was separated from free ACTH in this manner, the volume of the incubation mixture was increased to 1.5 ml with a final plasma concentration of 10%. Trasylol (FBA Pharmaceuticals Inc., New York) was added at a concentration (200 KIU/ml) that did not interfere with binding. After incubation was complete, 1.5 ml freshly prepared 20% polyethylene glycol (Carbowax 6000, Union Carbide Corp., New York) in 0.05 M phosphate buffer pH 7.4 containing 0.45% NaCl at 40C was added with a repipet (Labindustries, Berkeley, Calif). The tubes were mixed on a Vortex mixer (Scientific Industries, Inc., Queens Village, N. Y.) for 2 s, centrifuged at 6,000 g at 40C for 15 min, and the supernate decanted and discarded. The precipitate was counted in a Packard Auto-Gamma scintillation spectrometer (Packard Instrument Co., Inc., Downers Grove, Ill.). This method of separation was also adapted to situations in which small incubation volumes were adequate and the only carrier protein in the incubation mixtures was the 0.25% human serum albumin in the diluent and buffer solutions (13) (e.g., assays of plasma and tissue extracts, Sephadex fractions of tissue extracts, and purified or synthetic ACTH and melanocyte-stimulating hormone (MSH) analogues). A volume of cold (40C) phosphate buffer containing 150 ul of out-dated blood bank plasma sufficient to bring the total volume of the incubation mixture to 1.5 ml was added immediately before adding the polyethylene glycol.
A CTH antisera. The antisera used for radioimmunoassay and for neutralization and immunoadsorption experiments were chosen empirically on the basis of their binding affinities and their specificities for different portions of the ACTH molecule. Specificity was defined by determining the ability of a variety of synthetic analogues of ACTH and MSH to compete with labeled human ACTH (LernerUpton-Lande 8B) for binding sites on the antibody. The extreme N-terminal antiserum was the gift of Doctors L. H. Rees, D. Cook, and J. W. Kendall. It was developed by injecting a rabbit subcutaneously with synthetic a1"ACTH' (Cortrosyn, Organon, Inc., West Orange, N. J.) conjugated by the carbodiimide reaction to rabbit serum albumin and emulsified in complete Freund's adjuvant (Difco Laboratories, Detroit, Mich.). The N-terminal ACTH antiserum was raised in a guinea pig by subcutaneous injections of zinc-porcine ACTH (Organon, Inc.) emulsified in complete Freund's adjuvant, as previously described (13) . The two C-terminal antisera were both raised in rabbits in response to subcutaneous injections of partially purified human ACTH (Raben) emulsified in complete Freund's adjuvant. The available quantity of the first C-terminal antiserum was so limited that a second antiserum was required for further studies. The second antiserum was "mixed," with antibody populations that reacted both with the N-terminal and with the C-terminal portions of the ACTH molecule (13) . Therefore, the antiserum was adsorbed with aIMACTH 'In this study we have adhered to the conventions for nomenclature proposed by Dr. C. H. Li (35) for various analogues of ACTH and MSH. The first ACTH isolated from the pituitary of a given species is designated "a-ACTH" and the second, if one were to be found, "fi-ACTH," and so forth. Any polypeptide with an amino acid sequence similar to that of the a-ACTH of a given species is also designated "a-ACTH." A superscript is used to indicate the portion of the ACTH molecule represented by the analogue (for example, aU`ACTH) and a C-terminal amide, if present, is also indicated (for example, a7? 3NE2ACTH). If the analogue contains species-specific portions of the molecule, the appropriate species is indicated by a subscript (for example, aP9ACTH contains the C-terminal 15 amino acids of porcine ACTH).
Ectopic ACTH and ACTH Fragments covalently coupled to diazotized cellulose (17) ; 1.8 ml of the antiserum was diluted 1: 100 in 0.05 M phosphate buffer pH 7.4 and mixed with 1 mg a'-4ACTH coupled to diazocellulose. It was incubated at 4VC for 7 days while being stirred slowly with a Teflon-coated magnetic stirring bar. The mixture was then centrifuged, and the supernatant antiserum was aspirated from the immunoadsorbent pellet. The antiserum was similarly adsorbed four more times.
Imrnunoadsorption procedure. Immunoadsorption of Cterminal immunoreactive ACTH by the N-terminal ACTH antiserum was assessed by mixing standard quantities (1 ng) of various preparations with 0.2 ml of the N-terminal ACTH antiserum diluted 1: 100 in 0.05 M phosphate buffer pH 7.4. These mixtures were incubated for 5 days at 4VC. As a control in each experiment, an identical quantity of the same preparation was similarly incubated in a 1:100 dilution of nonimmune guinea pig serum. The materials incubated were partially purified extracts of two tumors, highly purified ai,ACTH, synthetic a'-"ACTH, and synthetic ap2-39ACTH (Ciba-Geigy, Ltd., Basel, Switzerland). After incubation, the peptides not bound to antibody were extracted from the incubation mixture by stirring with 5 mg silicic acid (Mallinckrodt Chemical Works, St. Louis, Mo.) (18) for 30 min at 4VC, centrifuging, and aspirating the supernatant medium, which was then reextracted with another 5 mg silicic acid. The pooled 10 mg silicic acid was washed three times with 2 ml distilled water at 40C. The peptides were eluted with 1 ml 40% acetic acid at 40C. The eluates were lyophilized and reconstituted in 0.001 N HCl containing 0.25%o human serum albumin. The reconstituted eluates were then assayed in the C-terminal ACTH radioimmunoassay. The degree of immunoadsorption of Cterminal immunoreactive material was determined by comparing the quantity remaining after incubation with the N- Gel filtration procedure. Partially purified extracts of tumors obtained at surgery from three patients with ectopic ACTH syndrome and an extract of a normal human pituitary were applied in 1% acetic acid to a Sephadex G-50 fine resin column 85 X 2.5 cm *at 250C, saturated with 100 mg bovine serum albumin applied in 1 ml 1% acetic acid at least 4 h previously. They were eluted with 1%o acetic acid by descending flow at a rate of 48 ml/h. The void volume of the column was 142 ml; 9.5-ml fractions were collected. Fractions were subjected both to bioassay and to radioimmunoassays. Reproducibility to within 9.5 ml was observed with repeated calibration of the column with reference standard ACTH, synthetic human 8-MSH and synthetic a-MSH. Recoveries of biologic ACTH activities for the standard and unknowns were 30-100%, averaging 61%o; recoveries of immunologic ACTH reactivities were 55-112%, averaging 92%.
Neutralization procedure. Neutralization of biologic ACTH activity by the C-terminal ACTH antiserum was assessed by mixing standard quantities of various preparations (usually 0.25 mU/rat) with the first C-terminal antiserum diluted 1: 5 with 0.05 M phosphate buffer pH 6.8 containing 0.5% bovine globulin. The mixtures were incubated at 370C for 30 min before injection into the hypophysectomized rat. As a control in each experiment, an identical quantity of the same preparation was similarly incubated in nonimmune rabbit serum diluted 1: 5 in the same buffer solution. The materials tested were three tumor extracts, highly purified human ACTH, and synthetic c1-24ACTH. The degree of neutralization of ACTH bioactivity was determined by comparing the adrenal-stimulating potency of the preparation that had been incubated with the Cterminal antiserum with that incubated with nonimmune rabbit serum (19) .
RESULTS

Characterization of ACTH antibody specificity 3
Extreme N-terminal ACTH antiserum. The results of studies of its specificity are shown in Fig. 1 . The antibodies reacted equally with all ACTH analogues (a-MSH, a'-ACTH, and aiACTH; also al"l'NH2ACTH and a"'ACTH, not shown) that share the N-terminal 13 amino acid sequence of ACTH, PhMSH, which contains amino acid sequence 4-10 of ACTH, and a1"'ACTH were far less reactive with the antibodies. Thus, this antiserum appeared to be directed toward the extreme N-terminal 1-13 amino acid sequence of the ACTH molecule.
N-terminal ACTH antiserum. The specificity of this antiserum is shown in Fig. 2 . Its affinity was limited to analogues of ACTH containing at least the 1-23 sequence 3The designations of the specificities of these antisera as "extreme N-terminal," "N-terminal," and "C-terminal" are intended as convenient abbreviations. Although these antisera are more completely characterized than any used in radioimmunoassay, it is still not possible to define the exact primary sequence requisite for maximum binding to any one of them. The sequences 1-13, 1-23, and 25-39, respectively, are the best approximations that can be made with the available data. of amino acids. Thus, a'-ACTH, a`t'ACTH, apl30-ACTH, and ahACTH all reacted with the antibodies to generate parallel competition curves. In contrast, a 10-ACTH, a-MSH (N-a-acetyl-alONH2ACTH), a1-16NH2_ ACTH, PhMSH, and a"-'ACTH had little affinity for the antibodies, and C-terminal ap"39ACTH failed to react. Thus, the antibodies appeared to be directed at the N-terminal 1-23 portion of the molecule. The antibodies also reacted fully with N-a-acetyl-al-'ACTH and with analogues having 1-D-serine and 4-norleucine substitutions, suggesting that the first four residues may not be critical for binding. It is interesting that ap17-39ACTH reacted with the antibodies, although with reduced binding affinity.
C-terminal ACTH antisera. Specificity analysis of the first antiserum revealed that it reacted with the C-terminal portion of the ACTH molecule. Four analogues that share an identical 8 amino acid C-terminal sequence, ahACTH, ap'39ACTH, ap17-ACTH, and ap25-3ACTH, all generated parallel competition curves (Fig. 3 ). In contrast, a"'2ACTH, ax"ACTH, a-MSH, a'-ACTH, a1-ACTH, jhMSH failed to displace labeled ahACTH from the antibodies. The fragments ap" ACTH and ap"ACTH were slightly more effective than equimolar quantities of 1-39 ACTH, yet they failed to displace all of the labeled aACTH from the antibodies. This appeared to be due to the presence of a very minor fraction of antibody that reacted wvith the N-terminal portion of the ACTH molecule, as demonstrated by the fact that complete displacement was achieved by the further addition of a'-1ACTH.
The specificity of the second antiserum before adsorption is shown in Fig. 4a . The antiserum was "mixed," with antibody populations that reacted both with the N-terminal a'24ACTH fragment and the C-terminal ap17-39ACTH and ap-39ACTH sequences. The specificity of this antiserum after immunoadsorption is shown in Fig. 4b . Although not all of the N-terminal antibodies were removed, the specificity of this antiserum was now similar to that of the first C-terminal antiserum, and its sensitivity was considerably greater than that of the first antiserum.
Precision of ACTH radioimmunoassays
Duplication. Six duplicate estimates of endogenous ACTH concentrations in four plasma pools in one assay yielded the results summarized in Table I . They are typical of the assays, in that they represent a single experiment, performed in a routine manner, and not the best of several experiments.
Replication. Replication of 32 plasma samples with levels ranging from 50 to 5,000 pg/ml in assays performed on different days yielded the following correlation coefficients: + 0.98 (extreme N-terminal), + 0.97 (N-terminal), and + 0.80 (C-terminal).
Assay of ACTH in tissue
Tumor tissue. Extracts of tumors from 32 patients with ectopic ACTH syndrome obtained at autopsy or at surgery were subjected to bioassay and to radioimmunoassays employing the extreme N-terminal, N-terminal, and C-terminal ACTH antibodies. tumor tissues. The competition .curves were parallel to those of highly purified ahACTH in all three radioimmunoassay systems. There was reasonably close agreement between the amounts of bioactive and extreme N-terminal, N-terminal and C-terminal immunoreactive ACTH found in the pituitary extracts (Table III) .
Assays of plasma ACTH
Since there was a disproportionately high concentration of extreme N-terminal and C-terminal immunoreactive ACTH material in the tumor extracts, it seemed possible that a similar discrepancy might be found in the circulating plasma of patients with the ectopic ACTH syndrome.
Plasma from patients with ectopic ACTH syndrome. Plasma or plasma extracts from 18 patients with ectopic ACTH syndrome were subjected to extreme N-terminal, N-terminal, and C-terminal radioimmunoassay. The competition curves generated by these materials were parallel to those of the ahACTH standard in each assay system. The results of the assays are summarized in Table IV . There was a consistent excess of both extreme N-terminal and C-terminal ACTH over N-terminal immunoreactive ACTH, with mean ratios of 3.0 and 3.3, respectively. In one patient (Gr) from whom sufficient plasma was obtained for bioassay, the value (2,900 pg/ml) agreed well with N-terminal immunoreactive ACTH.
Plasma from patients with Cushing's disease. As a control group, plasma or plasma extracts from 19 patients with Cushing's disease (pituitary ACTH-dependent Cushing's syndrome) were similarly assayed. The competition curves were parallel to those of standard ahACTH in all three radioimmunoassays. The results are COLUMN EFFLUENT VOLUME -ml FIGURE 8 Sephadex G-50 fine gel filtration elution pattern of an extract of an ectopic ACTH-producing tumor (Patient A. S.). The column was 85 X 2.5 cm; void volume was 142 ml. The total biologic ACTH activity in each 9.5 ml fraction is plotted at the top, the total biologic MSH activity (20) COLUMN EFFLUENT VOLUME -ml FIGURE 9 The bioactive ACTH and MSH, and the Cterminal, N-terminal, and extreme N-terminal immunoreactive ACTH in each 9.5 ml fraction eluted from a Sephadex G-50 fine resin column. The data are for an extract of the tumor removed at surgery from patient E. C. and are plotted in the same manner as in Fig. 8 . lecular weight appeared to be approximately 1,800 daltons. The fractions containing the immunoreactive N-terminal ACTH fragment had significant biologic MSH activity, but little a-MSH or PhMSH immunoreactivity, as previously reported (20) . Thus, in addition to bioactive ACTH, the three tumor extracts contained two components that appeared to be N-terminal and C-terminal fragments of ACTH.
Pituitary extract. An extract of a normal human pituitary gland, obtained at autopsy and frozen immediately, was applied to the same Sephadex G-50 fine column. The bioactive and immunoreactive ACTH eluted in the same fractions as reference standard ACTH (Fig. 11) . No higher molecular weight bioactive or immunoreactive ACTH materials were present, nor were there immunoreactive ACTH materials present that eluted later than bioactive ACTH from the column. Thus, the N-terminal and C-terminal fragments observed in the three tumor extracts were not present in the normal pituitary extract.
Neutralization of ACTH biologic activity
The C-terminal 15 or Fig. 8 .
ACTH, which possesses an immunoreactive 25-39 C-terminal sequence of amino acids, and synthetic a'"ACTH, which does not, were similarly incubated. The neutralization of ACTH was determined by comparing the biologic potency of the mixtures which had been incubated with the C-terminal ACTH antiserum with the potency of control mixtures incubated with equal concentrations of nonimmune rabbit serum (19) . The results are summarized in Table VI . Human 1-39 ACTH was largely neutralized by incubation with the antiserum, whereas 1-24 ACTH was not. Incubation with the C-terminal antiserum largely neutralized the biologic ACTH potency of the tumor extracts. Neutralization could be reversed by acidifying the incubation mixtures before injection into the rat, demonstrating that the ACTH was not destroyed, but was inactivated by reversibly binding to the antibodies (19) . signed to achieve partial purification (3, 4) . Thus, both hormones cause adrenal hypertrophy, both stimulate the release of corticosteroids from the adrenal of man and of the rat, both cause darkening of frog skin in vitro and in vivo, and both demonstrate in vitro lipolytic activity. The dose-response curves of the two hormones are parallel in the rat bioassay system, and the steroidogenic activity of both appears to be mediated by the intraadrenal formation of cyclic AMP. Ectopic ACTH, like pituitary ACTH, can be extracted from Results are expressed as percent of control mixtures incubated with nonimmune rabbit serum.
tissues with glacial acetic acid and can then be precipitated with ether. Both are adsorbed from dilute acetic acid onto Amberlite CG-50 cationic-exchange resin, from which they can be eluted with 50% acetic acid, or onto oxycellulose, from which they can be eluted with 0.1 N HCl. Both can be separated from MSH on a column of SE-Sephadex. Ectopic ACTH, like authentic pituitary ACTH, is stable at a pH of less than 2 but is relatively labile in alkaline solution.
Both are susceptible to inactivation by trypsin and chymotrypsin and are labile in plasma. Both can be dialyzed from plasma only at acid pH. Like pituitary ACTH, ectopic ACTH is readily inactivated by exposure to H202 but can be reactivated by cysteine, an observation that suggests methionine is an important constituent of the molecule (21) . Both ectopic ACTH and pituitary ACTH are inactivated by periodate, an observation suggesting that the N-terminal amino acid residue of both is serine (22) . Most previous reports of radioinmmunoassay of ACTH in the plasma or tumors of patients with the ectopic ACTH syndrome provide little qualitative information about the tumor hormone; either the specificities of the antisera were not well-documented, parallelism of the competition curves of the tumor ACTH with that of standard ACTH was not demonstrated, or simultaneous assays of biologic ACTH potency were not performed (23) (24) (25) (26) (27) (28) . The present study provides evidence that the tumors of patients with the ectopic ACTH syndrome produce a material that not only has biologic ACTH activity but also has at least three areas of immunochemical similarity to the authentic human pituitary ACTH molecule. The first of these is located in the extreme N-terminal sequence of amino acids 1-13, and the second in the extended N-terminal sequence 1-23; these two sequences encompass the steroidogenic portion of the ACTH molecule. The third area of immunochemical similarity is in the biologically inactive C-terminal sequence of amino acids 25-39. Since the C-terminal antiserum reacts equally well with porcine and human ACTH, the extreme C-terminal 8 amino acid sequences of which are identical, it may be presumed that the antibodies are directed toward this portion of the molecule.
There was generally good correlation between the quantities of bioactive ACTH and the quantities of Nterminal immunoreactive ACTH found in the tumor extracts and in normal human pituitaries. Modest disparities between the amounts of immunoreactive ACTH and the amounts of bioactive ACTH would not constitute an unexpected finding, since the receptor on the adrenal cell membrane presumably has different structural requirements for binding ACTH than does an antibody (8) . In contrast to the relatively close agreement between the amounts of bioactive ACTH and the amounts of extreme N-terminal and C-terminal immunoreactive ACTH found in the pituitary extracts, however, there were unexpected excesses of both immunoreactive ACTH components in several of the tumor extracts. Since we first reported the presence of excess C-terminal immunoreactive ACTH fragments in tumors of patients with the ectopic ACTH syndrome (4, 29) , a study has appeared which corroborates our findings (28). These authors described simultaneous bioassay and radioiminunoassays of ACTH in tumors of nine patients with ectopic ACTH syndrome. Two ACTH antisera were used, the specificities of which were similar to the N-terminal and C-terminal ACTH antisera employed in the present study. The average ratios of the amounts of N-terminal immunoreactive ACTH to the amounts of bioactive ACTH (1.6) and of the amounts of C-terminal immunoreactive ACTH to the amounts of bioactive ACTH (14.0) in their tumors were similar to those we have found.
There are a number of possible explanations for the presence of ACTH fragments in extracts of tumors causing ectopic ACTH syndrome. The excess of iminunoreactive materials in the tumor extracts might have been an artifact of the standard extraction procedure. However, the discrepancy was not observed in normal human pituitaries extracted by the same technique, and similar results have been observed using another extraction method (28) . A systematic study of the efficiency of various extraction procedures for these ACTH fragments has not been performed, however. The excess might have been the result of autolytic processes which cleaved the ACTH molecule somewhere in the 1-23 sequence, destroying both biologic activity and N-terminal immunoreactivity. However, several of the tumors in the present series and in that of Ratcliffe, Knight, Besser, Landon, and Stansfeld (28) were obtained at the time of surgery and were frozen immediately. Furthermore, a similar discrepancy was not observed in the extracts of pituitary glands, some of which were obtained as long as 5 h after death. It has been reported that proteolytic activity is higher in tumor tissue than in normal tissue (30, 31) , although neutral proteases, which might be expected to cause the greatest problem in the radioimmunoassay system, were not increased (31 (32) . One of these was somewhat larger (mol wt 2 7,800 daltons) than the 39 amino acid molecule (mol wt . 4,500 daltons) extracted from the pituitaries of man and other species. Others have more recently described a much larger immunoreactive "ACTH" in human tissues and plasma (33) . We found no immunoreactive or bioactive ACTH of this size in the glacial acetic acid extracts of normal human pituitary or of the three tumors examined in the present study.
The second material that eluted from the Sephadex G-50 fine resin was smaller (mol xvt 3,100) than human pituitary ACTH (mol wt = 4,539), had no biologic ACTH activity, and reacted only with the Cterminal ACTH antiserum. Although it eluted in fractions that contained standard PbhMSH, previous studies of these fractions revealed negligible amounts of bioactive MISH or immunoreactive PhMSH or a-MSH (20) .
This material is presumed to represent the 25 or 26 C-terminal amino acid sequence of ACTH (ahl4'ACTH or ahl 49ACTH), although determination of its exact composition must await more detailed chemical analyses.
The third material eluted from the resin column still later and appeared to have a molecular weight of about 1,800, corresponding to a polypeptide of 15 or 16 residues. This material had no detectable steroidogenic activity and reacted with the extreme N-terminal ACTH antiserum, but not with the N-terminal or C- (34) . As the length of the amino acid chain of ACTH is decreased from 24 to 13 residues by progressive deletion of the C-terminal amino acid residues (Table VII) , ACTH bioactivity is rapidly lost and MSH bioactivity is progressively increased. On the basis of the approximate molar concentration of the fragment as measured in the extreme N-terminal ACTH radioimmunoassay, its MSH potency is about 8% that of a-MSH. This is consistent with the predicted MSH activity of a fragment 14-15 residues in length. Thus, the unknown MSH previously reported from this laboratory (20) appears to be the N-terminal fragment of the ACTH molecule.
It was anticipated that the excessive quantities of extreme N-terminal and C-terminal ACTH fragments in the tumors might be reflected in plasma and thereby serve as a useful diagnostic test for ectopic ACTH production. Although there were threefold higher levels of immunoreactive ACTH as measured by these two assays than bV the N-terminal radioimmunoassay or by bioassay, similar ratios were found in the plasma of patients with Cushing's disease (Cushing's syndrome caused by excessive secretion of ACTH by the pituitary). It is not surprising to find more immunoreactive ACTH than bioactive ACTH in plasma, since we have found that the disappearance rate of biologic ACTH activity from plasma is more rapid than that of immunoreactive ACTH measured in two radioimmunoassay svstems (8) . It was remarkable, however, that the discrepancies found in the tumors were not reflected in the plasma. In patient Z. S., for example, the tumor extreme N/N and C/N ratios were 89 and 20, respectively, whereas the corresponding plasma ratios were only 1.5 and 2.5. This suggests that, if these fragments are produced in vivo, either the fragments are much more rapidly metabolized once they reach the circulation, or very small percentages of the fragments reach the circulation. Two lines of evidence suggest that the latter may be the correct hypotheis. First, our previous data indicate that ACTH fragments have a prolonged half-life in circulating plasma, not a shortened one (8) . Second, there has appeared to be no close correlation between the concentration of ACTH in the tumor and in the plasma of the same patient, either in our own experience or that of others (28) . ACTH has been found in postmortem tumor tissue of patients who were not suspected of having had ectopic ACTH syndrome in concentrations similar to those of patients in whom the syndrome was readily apparent (4, 28) . Thus, tumor concentrations of ACTH or ACTH fragments may not accurately reflect the rate of secretion of these polypeptides by the tumor.
The explanation for the presence of the ACTH fragments is not yet known. There are at least three possible mechanisms: faulty transcription or translation of the ACTH genome, resulting in the synthesis of both ACTH and ACTH fragments; proteolytic cleavage of intact ACTH after normal synthesis, either in vivo or after the tissue was removed; or inability of the tumor cell to condense efficiently two normal ACTH precursor molecules to form whole ACTH. The first seems unlikely, since each of the three tumors appeared to contain identical ACTH fragments. The second is a strong possibility, since the 14-18 sequence of ACTH is Gly-Lys-Lys-Arg-Arg, which contains bonds that can be cleaved by several known proteolytic enzymes.
The tumor cell may contain an enzyme not active in the pituitary ACTH-secreting cell, or the ACTH in the pituitary cell may be unavailable to an enzyme present in both it and the tumor cell, by being con-*tained within a secretory granule, for example. However, preliminary studies involving incubation of intact ACTH with a 105,000 g tumor cell cytosol preparation at 37°C rapidly destroyed biologic ACTH activity and produced immunoreactive ACTH fragments of many sizes, with no evidence for preferential production of these two specific fragments. The third possibility, while intriguing, suffers from the fact that there is as yet no evidence for such precursor subunits of ACTH in the normal pituitary. If their synthesis, rather than their subsequent condensation, were the rate-limiting step in pituitary ACTH synthesis, however, their turnover could be so rapid that they would never be present in more than trace quantities. These possibilities are currently being investigated.
It is apparent that tumors causing the ectopic ACTH syndrome may contain, in addition to ACTH that is indistinguishable from authentic pituitary ACTH, at least two ACTH fragments. One of these appears to be the C-terminal portion of the ACTH molecule and has no detectable biologic activity. The other appears to be the complementary N-terminal amino acid sequence. This fragment has negligible ACTH biologic activity, but has significant melanocyte-stimulating activity. Thus, tumors causing ectopic humoral syndromes may contain, not only intact hormones, but hormone fragments, some of which may have a spectrum of biologic activities and immunologic reactivities different from that of the parent hormones.
